Magnetic Resveratrol Liposomes as a New Theranostic Platform for Magnetic Resonance Imaging Guided Parkinson’s Disease Targeting Therapy

Resveratrol (3,5,4′-trihydroxy-trans-stilbene, Res), as a natural product and neuroprotective drug, plays important roles in the treatment of Parkinson's disease (PD). However, Res is seriously hindered by the blood–brain barrier (BBB), which limits the access of Res to the central nervous system. In addition, the differential diagnosis of PD has been considered one of the most challenging in neurology. Herein, a magnetic targeting drug nanocarrier, Fe3O4-modified Res liposomes (Res-lips@Fe3O4), was designed and fabricated. The factional anisotropy (FA) values and T2 relaxation time of the Res-lips@Fe3O4 treated rats were obtained by magnetic resonance imaging. The Res-lips@Fe3O4 possessed high drug capability and stability, which exhibited strong magnetic response properties. Res-lips@Fe3O4 displayed sustained and slow drug release in vitro. In vivo experiments showed that the Res-lips@Fe3O4 could effectively cross the BBB and increase the drug content at the target site under the external magnetic field. FA values and T2 relaxation time also demonstrated the best therapeutic effect of the magnetic Res liposomes. Therefore, the Res-lips@Fe3O4 combining with an external magnetic field will provide a potential platform to cross the BBB and effectively treat cerebral disease.